ARL6IP5 Antibody, FITC conjugated

Overview

This is a polyclonal anti-ARL6IP5 antibody raised in Rabbit, conjugated with FITC. Designed to detect ARL6IP5 in Human, supporting researchers in signal transduction contexts.

Key elements and design rationale

• Immunogen: Recombinant Human PRA1 family protein 3 protein (136-188AA) — determines the epitope region recognized; confirm epitope compatibility with your sample preparation and expected PTMs.
• Host (Rabbit): Requires anti-rabbit-IgG secondary reagents. Mismatched secondaries result in no signal. Consider host species when multiplexing.
• Polyclonal: Recognizes multiple epitopes — robust signal across varied preparations, with inherent lot-to-lot variability. Isotype controls and lot qualification recommended.
• Isotype (IgG): Secondary antibodies and isotype controls must match IgG from Rabbit. Relevant for multiplexing and Protein A/G compatibility.
• Purification (Protein G purification): Reduces non-specific immunoglobulin populations, improving signal-to-noise in quantitative immunoassay formats.
• FITC conjugate: Direct fluorescence (Ex ~490 nm / Em ~525 nm). Susceptible to photobleaching — use antifade reagents; protect from light.

Biological background

ARL6IP5 (also known as Addicsin, ADP ribosylation factor like protein 6 interacting protein 5, ADP ribosylation like factor 6 interacting protein 5, ADP-ribosylation factor-like protein 6-interacting protein 5, Aip 5, Aip-5, Aip5, ARL 6 interacting protein 5, ARL-6-interacting protein 5, ARL6IP5, Cytoskeleton related vitamin A responsive protein, Cytoskeleton-related vitamin A-responsive protein, Dermal papilla derived protein 11, Dermal papilla-derived protein 11, DERP 11, DERP11, Glutamate transporter EAAC1-interacting protein, Glutamate transporter EEAC 1 associated protein, Glutamate transporter EEAC1 associated protein, GTRAP3 18, GTRAP3-18, Hp 22, Hp22, HSPC 127, HSPC127, JM 5, JM5, JMX, JWA, PRA 1 domain family 3, PRA 2, PRA1 domain family 3, PRA1 family protein 3, PRA2, PRAF 3, PRAF3, PRAF3_HUMAN, Prenylated Rab acceptor protein 2, Protein JWa, Putative MAPK activating protein PM27, Putative MAPK-activating protein PM27) is a protein studied in Human systems. Expression levels, subcellular localization, and post-translational modifications vary across cell types, tissues, and disease states — factors that influence antibody-based detection outcomes. Researchers are encouraged to consult UniProt, NCBI Gene, and primary literature for current annotation of ARL6IP5 biology relevant to signal transduction.

Common research applications

• Refer to the product datasheet for confirmed application data.

Notes for experimental interpretation

• Isotype controls: Include IgG from Rabbit at equivalent concentration to assess non-specific background.
• Cross-reactivity/isoforms: Polyclonal preparations may cross-react with related proteins or isoforms — validate with siRNA KD, KO lysate, or recombinant protein controls.
• Matrix effects: Sample matrix (serum, plasma, lysate, homogenate) may influence performance; pilot dilution linearity and spike-recovery experiments before full quantitative studies.
• Species reactivity: Confirmed for Human; extrapolation to untested species requires empirical validation.

This product is a polyclonal antibody purified from rabbit antiserum.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.